8-K: CDT Equity Announces 1-for-8 Reverse Stock Split

CDT Equity Inc. will implement a 1-for-8 reverse stock split to increase its stock price and facilitate future capital raises.

Summary

• CDT Equity Inc. filed a certificate of amendment to its Second Amended and Restated Certificate of Incorporation to effectuate a 1-for-8 reverse stock split of its common stock.
• The reverse stock split will become effective on October 10, 2025, at 5:00 p.m. Eastern Time.
• Common Stock is expected to begin trading on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis on October 13, 2025, at market open under the existing ticker symbol, CDT.
• Every eight shares of issued and outstanding common stock will be combined into one share of common stock.
• The par value of the common stock will remain unchanged at $0.0001 per share.
• Proportional adjustments will be made to the number of shares of common stock issuable upon the exercise of equity awards, convertible securities, and warrants, as well as the applicable exercise price and shares authorized for equity incentive plans.
• No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment equal to the fraction multiplied by the closing price per share on Nasdaq on October 10, 2025 (as adjusted for the split).
• The Company's post-Reverse Stock Split Common Stock CUSIP number will be 20678X403.
• The number of outstanding shares of common stock will be reduced to approximately 1,352,448 after the effectiveness of the reverse stock split.

Sentiment

Score: 6

Explanation: The reverse stock split is a strategic move to potentially increase stock price and facilitate capital raising, which is generally positive for long-term strategy. However, reverse splits can sometimes be viewed negatively by the market, and the actual impact on stock price and capital raise success remains to be seen. The explicit mention of capital raising potential is a positive signal for future growth.

Positives

• The board of directors expects the reverse stock split will increase the amount of funds the Company might be able to raise to execute its strategy.
• The reverse stock split is approved by Nasdaq, which may help maintain listing compliance and improve market perception.

Risks

• The effect that the reverse stock split may have on the price of the Company's common stock.
• The ability or inability to maintain the listing of CDT's securities on Nasdaq.
• The ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by competition.
• The ability of the combined company to grow and manage growth economically and hire and retain key employees.
• Risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all.
• Changes in applicable laws or regulations.
• The possibility that CDT may be adversely affected by other economic, business, and/or competitive factors.
• Other risks and uncertainties identified in other filings made with the U.S. Securities and Exchange Commission.

Future Outlook

The Company expects the reverse stock split to increase the amount of funds it might be able to raise to execute its strategy. It also anticipates its common stock will continue trading on Nasdaq under the symbol CDT.

Management Comments

• The directors expect that the reverse stock split will increase the amount of funds the Company might be able to raise to execute its strategy.

Industry Context

Reverse stock splits are often implemented by companies to increase their per-share stock price, primarily to meet minimum bid price requirements for continued listing on exchanges like Nasdaq, or to make the stock more attractive to institutional investors who may have policies against investing in investing in 'penny stocks.' This move by CDT Equity Inc. aligns with a strategy to improve its market perception and facilitate future capital raising, a common practice in the biopharmaceutical sector where significant capital is often required for development.

Corporate Governance

Stakeholder Impact

• Shareholders will see their number of shares reduced by a 1-for-8 ratio, but the per-share price is expected to increase proportionally. Fractional shares will be cashed out. The move aims to make the stock more attractive for institutional investment and potentially facilitate future capital raises, which could benefit long-term shareholders.
• Employees holding equity awards will have their awards, convertible securities, and warrants proportionally adjusted to reflect the split, maintaining their intrinsic value.
• The Company (CDT Equity Inc.) aims to achieve a higher per-share stock price, potentially meet Nasdaq listing requirements, and improve its ability to raise capital for strategic initiatives.

Next Steps

• Common Stock to begin trading on Nasdaq on a Reverse Stock Split-adjusted basis on October 13, 2025.
• The transfer agent (VStock Transfer, LLC) will serve as the exchange agent for the reverse stock split.
• Continued execution of strategy, potentially including capital raises.
• Advancing high-potential therapeutic assets through scientific innovation and strategic partnerships.
• Creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Key Dates

Recommendation

The reverse stock split is a strategic corporate action aimed at improving the company's stock profile and facilitating future capital raises. While it addresses potential listing concerns and opens doors for financing, it does not inherently change the company's underlying value or operational performance. Investors should hold to observe the market's reaction to the split, the company's ability to execute its strategy with potential new capital, and progress on its biopharmaceutical development pipeline before making further investment decisions. The success of the capital raise and the impact on the stock price are still uncertain.

Keywords

Reverse Stock Split, CDT Equity Inc., Nasdaq, Common Stock, Capital Raise, Biopharmaceutical, Equity Awards, Warrants, Corporate Governance